CoChat

Liver organoids: established tools for disease modeling and drug development

Open access
Sun, Xi-Cheng, Kong, De-fu, Zhao, Jie, Faber, Klaas Nico, Xia, Qiang, He, Kang · 2023 · Hepatology Communications

The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.

Abstract

In the past decade, liver organoids have evolved rapidly as valuable research tools, providing novel insights into almost all types of liver diseases, including monogenic liver diseases, alcohol-associated liver disease, metabolic-associated fatty liver disease, various types of (viral) hepatitis, and liver cancers. Liver organoids in part mimic the microphysiology of the human liver and fill a gap in high-fidelity liver disease models to a certain extent. They hold great promise to elucidate the pathogenic mechanism of a diversity of liver diseases and play a crucial role in drug development. Moreover, it is challenging but opportunistic to apply liver organoids for tailored therapies of various liver diseases. The establishment, applications, and challenges of different types of liver organoids, for example, derived from embryonic, adult, or induced pluripotent stem cells, to model different liver diseases, are presented in this review.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hc9.0000000000000105

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Scheme of liver organoid formation. Adult stem cells (ASCs), primary hepatocytes, or cholangiocytes could be obtained from primary liver tissue, intrahepatic/extrahepatic bile duct, gallbladder, or human bile by means of surgical resection, needle biopsy, and endoscope brushing. After mechanical or enzymatic dissociation, single hepatocytes or cholangiocytes are plated on ECM that contains exclusive growth factors and chemical molecules. In addition, liver organoids can be derived from PSCs, including iPSCs and ESCs. PSCs are firstly induced into definitive endoderm and then into hepatoblasts, which can differentiate into hepatocyte or cholangiocyte organoids with careful modulation of specific signaling pathway modeling liver development (relative growth factors in the medium are listed above). Abbreviations: BMP4, bone morphogenetic protein 4; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; PSCs, pluripotent stem cells.
FIGURE 1 Scheme of liver organoid formation. Adult stem cells (ASCs), primary hepatocytes, or cholangiocytes could be obtained from primary liver tissue, intrahepatic/extrahepatic bile duct, gallbladder, or human bile by means of surgical resection, needle biopsy, and endoscope brushing. After mechanical or enzymatic dissociation, single hepatocytes or cholangiocytes are plated on ECM that contains exclusive growth factors and chemical molecules. In addition, liver organoids can be derived from PSCs, including iPSCs and ESCs. PSCs are firstly induced into definitive endoderm and then into hepatoblasts, which can differentiate into hepatocyte or cholangiocyte organoids with careful modulation of specific signaling pathway modeling liver development (relative growth factors in the medium are listed above). Abbreviations: BMP4, bone morphogenetic protein 4; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; PSCs, pluripotent stem cells.CC BY-NC-ND · PubMed Central
FIGURE 2 Biomedical applications of liver organoids. Healthy liver organoids derived from healthy donors can mimic organogenesis, and thus hold great promise for developmental science. Healthy organoid transplantation into injured individuals showed terrific therapeutic effects, indicating that healthy organoids are prospective in regenerative medicine. Both healthy organoids and diseased organoids derived from patients with different types of liver diseases, including monogenic liver diseases, infectious hepatitis, AALD, MAFLD, and liver carcinoma, could be cryopreserved as biobanks for further experiments such as disease mechanism investigation. Diseased organoids are also subjected to drug screening and toxicity testing, indicating great candidates for personalized treatment. Abbreviations: AALD, alcohol-associated liver disease; MAFLD, metabolic-associated fatty liver disease.
FIGURE 2 Biomedical applications of liver organoids. Healthy liver organoids derived from healthy donors can mimic organogenesis, and thus hold great promise for developmental science. Healthy organoid transplantation into injured individuals showed terrific therapeutic effects, indicating that healthy organoids are prospective in regenerative medicine. Both healthy organoids and diseased organoids derived from patients with different types of liver diseases, including monogenic liver diseases, infectious hepatitis, AALD, MAFLD, and liver carcinoma, could be cryopreserved as biobanks for further experiments such as disease mechanism investigation. Diseased organoids are also subjected to drug screening and toxicity testing, indicating great candidates for personalized treatment. Abbreviations: AALD, alcohol-associated liver disease; MAFLD, metabolic-associated fatty liver disease.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 112 references

Cited by

See all 44

Metadata

Authors
Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K.
Affiliations
  • Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Shanghai Jiao Tong University (CN)
  • University Medical Center Groningen (NL)
Corresponding author
  • Faber, Klaas Nico
  • Xia, Qiang
  • He, Kang
Venue
Hepatology Communications
Published
2023-03-24
Volume
7
Issue
4
ISSN
2471-254X (ISSN-L)
OpenAlex
W4360993648
Cited by
37
References
114
Citations by year
2026: 11 · 2025: 14 · 2024: 8 · 2023: 4
FWCI
1.60
Type
journal article
Language
en
Open access
Locations
  • Hepatology Communications (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
Funders
Shanghai Municipal Health Commission
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
liver organoids, liver disease modeling, drug development, alcoholic liver disease, metabolic-associated fatty liver disease, viral hepatitis, liver cancer, induced pluripotent stem cells, embryonic stem cells, adult stem cells, personalized treatment
MeSH terms
Drug Development, Adult, Humans, Liver Neoplasms, Organoids, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver organoids: established tools for disease modeling and drug development. https://app.cochat.ai/papers/10.1097/hc9.0000000000000105
The paper
Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023). Liver organoids: established tools for disease modeling and drug development. Hepatology Communications. https://doi.org/10.1097/hc9.0000000000000105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.